Synthesis and evaluation of [Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer.

We radiolabeled a ligand, PSMA-617, of prostate-specific membrane antigen (PSMA) with copper-64 (Cu), to evaluate the metabolism, biodistribution, and potential of [Cu]PSMA-617 for PET imaging of prostate cancer. [Cu]PSMA-617 was synthesized by heating PSMA-617 with [Cu]CuCl in buffer solution at 90°C for 5 min. uptake was determined in two cell lines of prostate cancer. regional distributions were determined in normal and tumor-bearing mice. High radiolabeling efficiency of Cu for PSMA-617 yielded [Cu]PSMA-617 with >99% radiochemical purity. cellular uptake experiments demonstrated the specificity of [Cu]PSMA-617 for PSMA-positive LNCaP cells. Biodistribution observations of normal mice revealed high uptake of radioactivity in the kidney and liver. PET with [Cu]PSMA-617 visualized tumor areas implanted by PSMA-positive LNCaP cells in the mice. Two hours after the injection of [Cu]PSMA-617 into mice, a radiolabeled metabolite was observed in the blood, liver, urine, and LNCaP tumor tissues. [Cu]PSMA-617 was easily synthesized, and exhibited a favorable biodistribution in PSMA-positive tumors. Although this radioligand shows slow clearance for kidney and high liver uptake, change of its chelator moiety and easy radiolabeling may enable development of new Cu or Cu-labeled PSMA ligands for imaging and radiotherapy.